[{"id":"c57ea625-cd33-4c56-acff-cfd618294813","acronym":"","url":"https://clinicaltrials.gov/study/NCT05492682","created_at":"2022-08-08T11:56:49.629Z","updated_at":"2024-07-02T16:35:23.644Z","phase":"Phase 1","brief_title":"START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer","source_id_and_acronym":"NCT05492682","lead_sponsor":"Valo Therapeutics Oy","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/02/2023","start_date":" 02/02/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-01-12"}]